Ligand validation:2I20

LI1: 1-[2,6,10.14-TETRAMETHYL-HEXADECAN-16-YL]-2-[2,10,14-TRIMETHYLHEXADECAN-16-YL]GLYCEROL

LI1 is a Ligand Of Interest in 2I20 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2I20_LI1_A_613	34%	60%	0.121	0.929	0.48	1.04	-	1	0	1	29%	0.2889
2I20_LI1_A_602	30%	12%	0.177	0.857	1.04	2.96	2	9	16	1	91%	0.9111
2I20_LI1_A_607	28%	45%	0.153	0.831	1.07	1.04	2	3	1	0	84%	0.8444
2I20_LI1_A_601	26%	40%	0.161	0.854	1.11	1.23	2	4	5	2	71%	0.7111
2I20_LI1_A_606	20%	70%	0.145	0.896	0.47	0.68	-	-	2	0	18%	17.78
2I20_LI1_A_612	19%	43%	0.186	0.887	1.06	1.16	1	2	1	0	40%	0.4
2I20_LI1_A_603	16%	43%	0.171	0.849	1.08	1.13	1	1	6	0	40%	0.4
2I20_LI1_A_611	9%	35%	0.191	0.798	1.13	1.41	1	5	4	1	38%	0.3778
2I20_LI1_A_605	9%	71%	0.17	0.811	0.45	0.65	-	-	0	0	18%	17.78
2I20_LI1_A_609	8%	39%	0.194	0.78	1.16	1.2	1	2	0	0	36%	0.3556
2I20_LI1_A_608	4%	41%	0.255	0.754	1.07	1.21	1	3	2	0	40%	0.4
2I20_LI1_A_604	4%	41%	0.235	0.725	1.12	1.18	1	2	1	0	36%	0.3556
2I20_LI1_A_610	1%	36%	0.349	0.448	1.25	1.25	3	4	15	0	89%	0.8889
3T45_LI1_B_604	36%	62%	0.142	0.852	0.6	0.85	-	1	3	0	89%	0.8889
6G7I_LI1_A_305	27%	63%	0.09	0.884	0.72	0.68	-	-	1	0	18%	17.78
3NSB_LI1_A_1008	26%	77%	0.097	0.897	0.3	0.6	-	-	0	0	11%	11.110000000000001
4X31_LI1_A_612	25%	79%	0.162	0.906	0.52	0.34	-	-	1	0	40%	0.4
6G7H_LI1_A_306	25%	62%	0.131	0.896	0.63	0.82	-	-	0	0	27%	0.2667
4JQ6_LI1_B_302	27%	78%	0.11	0.883	0.28	0.6	-	-	2	0	29%	0.2889

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.